Vectura Group confirms an announcement by partner Novartis that new data shows for the first time that the rate of treatment persistence for patients using the innovative Sandoz AirFluSal Forspiro respiratory inhaler is more than twice as high as for the reference product.
The results are reported in the latest edition of the leading Journal of Allergy and Clinical Immunology: In Practice. The comparative analysis study is the largest European Real-World Evidence (RWE) study ever conducted in asthma and COPD (chronic obstructive pulmonary disease).
The study, entitled "Comparative analysis of persistence to treatment among patients with asthma or COPD receiving AirFluSal Forspiro or Seretide Diskus salmeterol / fluticasone propionate combination therapy", concluded that patients using the Sandoz device showed a persistence rate of 22.9%, compared to 10.5% for those using the reference product device.
The study was designed to retrospectively analyse persistence rates between the two devices, using dispensing datas from a large German pharmacy database.
While retrospective database analyses have some limitations, the strengths of this data include the fact that 11,744 patients were included in a matched pair analysis, controlled for gender, age and month of treatment initiation (to limit seasonal effects).
All patients were first time users of salmeterol/fluticasone propionate and persistence to treat was analysed for a 12 month period.
AirFluSal Forspiro has been launched to date in approximately 30 countries, in Europe and elsewhere.
At 9:59am: (LON:VEC) Vectura Group PLC share price was -1.7p at 130.4p